$0.82
+0.04 (+5.24%)
Open$0.78
Previous Close$0.78
Day High$0.87
Day Low$0.78
52W High$21.04
52W Low$17.58
Volume—
Avg Volume92.2K
Market Cap3.18M
P/E Ratio37.76
EPS$0.53
SectorBiotechnology
Analyst Ratings
Strong Sell
8 analysts
Price Target
+2,468.8% upside
Current
$0.82
$0.82
Target
$21.09
$21.09
$14.27
$21.09 avg
$34.90
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 557.3K | 516.3K | 473.8K |
| Net Income | 76.7K | 85.4K | 67.5K |
| Profit Margin | 13.8% | 16.5% | 14.2% |
| EBITDA | 122.1K | 108.8K | 88.6K |
| Free Cash Flow | 55.8K | 59.0K | 42.6K |
| Rev Growth | +2.4% | +15.9% | +18.6% |
| Debt/Equity | 0.52 | 0.64 | 0.60 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |